Composition containing PQQ, application thereof and skin care product

Abstract

The present invention relates to the field of cosmetics technology, particularly to compositions containing PQQ, their applications, and skin care products. The present invention provides a composition of pyrroloquinoline quinone or its sodium salt and pyrroloquinoline lipopeptide sodium. This composition exhibits excellent permeability and stability, while exhibiting significant synergistic effects in antioxidant, whitening, and antibacterial properties. It has broad application prospects in the cosmetics field. Furthermore, the preparation method of this composition is simple and easy to operate, making it suitable for industrial production.

Description

Technical Field

[0001] The present invention relates to the technical field of cosmetics, and in particular to a composition containing PQQ, applications thereof, and skin care products. Background Art

[0002] With the rapid development of cosmetics technology, traditional cosmetic raw materials can no longer meet the growing demand for cosmetic efficacy, and it is also difficult to meet consumers' requirements for the effectiveness of specific efficacy. In existing cosmetic composition research, although researchers have developed a variety of ingredient combinations to achieve multiple efficacy, these compositions have many problems in practical application. Synergistic effects are not obvious, and the interactions between different ingredients have not been fully optimized, which cannot maximize the efficacy of each ingredient, limiting the improvement of the overall efficacy of the product. In addition, there is still considerable room for improvement in the stability, safety, and absorption effect of cosmetics.

[0003] Pyrroloquinoline quinone disodium salt (PQQ-2Na) is a water-soluble vitamin-like compound with potent antioxidant activity. It can inhibit the production of free radicals and scavenge existing ones, protecting cells from oxidative damage. Despite its numerous excellent antioxidant and other physiological properties, research into its application in cosmetics has lagged significantly. While the cosmetics industry is continuously developing research on the application of various functional ingredients, the application of PQQ-2Na remains relatively rudimentary. In particular, research into ingredient synergies has yet to identify any substance that can synergize with PQQ-2Na to further enhance its efficacy or expand its application. Therefore, there is significant room for development in the development of cosmetic compositions using PQQ-2Na that simultaneously achieve multiple benefits, including antioxidant, whitening, soothing, and antibacterial properties. Summary of the Invention

[0004] In view of this, the technical problem to be solved by the present invention is to provide a composition and its application and skin care product.

[0005] The composition provided by the invention comprises pyrroloquinoline quinone or its sodium salt and subtilisin sodium.

[0006] The present invention combines pyrroloquinoline quinone or its sodium salt with subtilisin sodium. Subtilisin sodium acts as a biosurfactant, reducing the surface tension between the active ingredient and the skin. Compared to other surfactants, subtilisin sodium can more effectively facilitate the penetration of PQQ-2Na through the skin barrier. Furthermore, the addition of subtilisin sodium can further stabilize pyrroloquinoline quinone or its sodium salt.

[0007] In the present invention, the mass ratio of pyrroloquinoline quinone or its sodium salt to subtilisin sodium is (0.02-0.1): (0.05-0.5).

[0008] In the present invention, pyrroloquinoline quinone disodium salt (PQQ-2Na) is used to verify the efficacy of the composition.

[0009] In some embodiments, the mass ratio of pyrroloquinoline quinone disodium salt (PQQ-2Na) pyrroloquinoline quinone disodium salt and subtilisin sodium is 0.02: (0.2-0.4) or 0.1: (0.05-0.5).

[0010] In a specific embodiment, the mass ratio of pyrroloquinoline quinone disodium salt to subtilisin sodium is 0.02: (0.2~0.3), or 0.02: (0.3~0.4), or 0.1: (0.05~0.1), or 0.1: (0.05~0.3), or 0.1: (0.05~0.5), or 0.1: (0.1~0.3), or 0.1: (0.1~0.5), or 0.1: (0.3~0.5).

[0011] In some specific embodiments, the mass ratio of pyrroloquinoline quinone disodium salt to subtilisin sodium is 0.02:0.2, or 0.02:0.3, or 0.02:0.4, or 0.1:0.05, or 0.1:0.1, or 0.1:0.3, or 0.1:0.5.

[0012] The present invention proves through experiments that, under a specific ratio, pyrroloquinoline quinone disodium salt and subtilisin sodium can produce good synergistic effects in terms of anti-oxidation, inhibition of tyrosinase activity and inhibition of harmful bacteria.

[0013] Furthermore, the present invention also provides the use of the composition in preparing skin care products.

[0014] In the present invention, the skin care product has the effects of soothing, anti-oxidation, whitening and / or antibacterial.

[0015] In an embodiment of the present invention, the antibacterial activity includes anti-Staphylococcus aureus and / or Propionibacterium acnes.

[0016] In an embodiment of the present invention, the anti-oxidation includes scavenging free radicals. In a specific embodiment, the free radical is DPPH.

[0017] In view of the functions of the composition of the present invention, it also has the effects of anti-aging, anti-acne, anti-allergy or redness removal.

[0018] In an embodiment of the present invention, the whitening comprises inhibiting tyrosinase activity.

[0019] In the present invention, the skin care products include: cleansing skin care products, nursing skin care products, or beauty / cosmetic skin care products. Cleansing skin care products include: at least one of: facial cleanser, facial cleanser, makeup remover oil, makeup remover liquid, makeup remover milk, makeup remover lotion, cleansing cream, cleansing honey, facial mask, bath soap, hand soap, cleansing gel, floral water, cleansing powder, and cleansing powder; nursing skin care products include: at least one of: skin cream, skin cream, skin lotion, toner, facial mask, skin gel, moisturizing oil, massage essential oil, massage base oil, floral water, prickly heat powder, and talcum powder; and beauty / cosmetic skin care products include: at least one of: pressed powder, rouge, eye shadow, eye cream, eyeliner, liquid eyeliner, eyebrow pencil, eyebrow powder, perfume, cologne, scented powder, loose powder, concealer stick, concealer cream, liquid foundation, cream foundation, powder stick, powder stick, blush, and powder cream.

[0020] Furthermore, the present invention also provides a skin care product, which includes the above-mentioned composition and auxiliary materials.

[0021] In the skin care product of the present invention, the mass fraction of the aforementioned composition is 0.15% to 0.6%. For example, the mass fraction of the aforementioned composition is 0.15%, 0.2%, 0.22%, 0.32%, 0.4%, 0.42% or 0.6%.

[0022] In the skin care product of the present invention, the excipients include, but are not limited to, purified water, surfactants, humectants, thickeners, oils, lipids, esters, waxes, chelating agents, antioxidants, pH adjusters, preservatives, pigments, and fragrances. In a specific embodiment, the excipients include pentylene glycol and water.

[0023] Furthermore, the present invention also provides a skin care method, which comprises applying the above-mentioned skin care product on the skin surface.

[0024] As a feasibility example, the administration methods of the present invention include but are not limited to smearing, spraying, wiping, spotting, patting, massaging, applying, spraying, and injection (such as microneedle introduction).

[0025] As a feasible case, the skin includes but is not limited to facial skin, neck skin, hand skin, arm skin, leg skin, foot skin, shoulder skin, back skin, chest skin, abdominal skin, skin around the ears, lip skin, skin around the eyes, elbow skin, knee skin, ankle skin, scalp, skin around the nails, areola skin or private parts skin.

[0026] The present invention provides a composition of pyrroloquinoline quinone or its sodium salt and pyrroloquinoline lipopeptide sodium. This composition exhibits excellent permeability and stability, and exhibits significant synergistic effects in terms of antioxidant, whitening, and antibacterial properties. It has broad application prospects in the cosmetics field. Furthermore, the preparation method of this composition is simple and easy to operate, making it suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Shows the cumulative permeability of PQQ-2Na for 24 h;

[0028] Figure 2 Indicates the stimulation intensity of each group;

[0029] Figure 3 The tyrosinase inhibition effect and DPPH free radical scavenging effect of each group are shown. DETAILED DESCRIPTION

[0030] The present invention provides compositions containing PQQ, their applications, and skin care products. Those skilled in the art can draw upon the present disclosure and appropriately modify process parameters to achieve these results. It is particularly important to note that all similar substitutions and modifications readily apparent to those skilled in the art are considered encompassed by the present invention. The methods and applications of the present invention have been described through preferred embodiments. It is readily apparent that those skilled in the art will be able to modify, adapt, and combine the methods and applications herein to implement and apply the present technology without departing from the present disclosure, spirit, and scope.

[0031] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0032] It should be understood that in various embodiments of the present invention, the size of the serial number does not mean the order of execution. Some or all steps can be executed in parallel or sequentially. The execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of this application.

[0033] The numerical ranges and parameters involved in this disclosure are presented as precisely as possible in the specific examples. However, any numerical value inherently and inevitably contains standard deviations resulting from individual testing methods. Therefore, unless otherwise expressly stated, it should be understood that all numerical ranges or specific data used in this disclosure are subject to reasonable deviation within a certain range, for example, within ±10%, ±5%, ±1%, or ±0.5%.

[0034] Some cases are recorded in the examples and comparative examples of the present invention. The examples show certain implementation methods of the present invention. However, this does not mean that the effects of the present invention can only be achieved in these cases. In fact, any concentration of each component between the two endpoint values ​​shown in the examples can achieve good results. Among the cases with relatively good effects, the mass ratio of PQQ-2Na to subtilisin sodium is 0.02:0.2, 0.02:0.3 or 0.02:0.4. The following examples also list some cases with poor results in the experiments, such as using different components and different ratios. However, the effects of these attempts are not as good as those under the ratios described above, and will not be repeated here. The present invention is further described below in conjunction with the examples:

[0035] Examples 1-7

[0036] The mass fractions of the raw materials in Examples 1 to 7 are shown in Table 1:

[0037] Table 1 Mass fraction of each raw material in Examples 1 to 7

[0038]

[0039] The preparation method comprises: weighing subtilisin sodium, pentanediol and PQQ-2Na in sequence, adding them into water and stirring until the PQQ-2Na is completely dissolved, thereby obtaining the composition.

[0040] Comparative Examples 1-11

[0041] Pentanediol, PQQ-2Na and other components were weighed in sequence and added to water, and stirred until PQQ-2Na was completely dissolved to prepare Comparative Examples 1-11.

[0042] Other components include penetration enhancers: ethoxydiglycol, bis-diethoxydiglycol cyclohexane 1,4-dicarboxylate, emulsifiers: polysorbate-80, polyglycerol-10 laurate, and rhamnolipid. The proportions of the raw materials used in Comparative Examples 1 to 11 are shown in Table 2:

[0043] Table 2 Mass fraction of each raw material in Comparative Examples 1 to 11

[0044]

[0045] Efficacy verification

[0046] 1. Stability test

[0047] The solutions of Examples 1-4 and Comparative Examples 1-6 were filled into 30ml plastic bottles and exposed to high temperatures of 4°C and 48°C for 15 days. The samples were tested for physical and chemical properties and changes in appearance. The PQQ-2Na content of the samples before and after the high and low temperature cycles was quantified by liquid chromatography, and the residual PQQ-2Na percentage (%) after the stability test was determined. The results are shown in Table 3:

[0048] Table 3 Stability test results of each group

[0049]

[0050] Comparing Examples 1-4 with Comparative Examples 1-6, it is shown that the compatibility of subtilisin sodium with PQQ-2Na is very good, the activity of PQQ-2Na can be maintained, and the solubility of PQQ-2Na can be improved, making the system more stable; Comparing Examples 4 with Comparative Examples 1-6, Comparative Example 2 (ethoxydiglycol), Comparative Example 4 (polysorbate-80), and Comparative Example 6 (rhamnolipid) have a PQQ-2Na retention rate of less than 90% at 48 ° C for 15 days, and have poor high-temperature compatibility with PQQ-2Na; Comparative Example 5 (polyglycerol-10 laurate) has polyglycerol-10 laurate precipitation at low temperatures, and has poor low-temperature compatibility; Comparative Example 3 (bis-diethoxydiglycol cyclohexane 1,4-dicarboxylate) has a high and low temperature PQQ-2Na retention rate of more than 90% for 15 days, and has relatively good compatibility with PQQ-2Na.

[0051] 2. Permeability test

[0052] Sample preparation: the samples prepared in Examples 1-4 and Comparative Examples 1 and 3 are ready for use; receiving solution (PBS), isolated suckling pig skin, and drug transdermal diffusion tester.

[0053] Experimental steps: 1) Soak the pig skin taken out of the refrigerator in physiological saline for 5 minutes. After the pig skin becomes soft, set it aside for use; 2) Connect the water bath, set the parameters (37℃, 400-600rpm), and start preheating in advance; 3) Cut the transdermal membrane of appropriate size and place it in the middle of the two half-cells (pay attention to the direction of the skin); 4) Adjust the fixture so that the two half-cells and the membrane are gradually tightened; 5) Add the sample and the receiver solution; 6) Fix the connected two half-cells on the top of the magnetic stirring table; 7) Set the stirring parameters and start working; 8) Take 1 mL of the receiving solution at each point 1, 2, 4, 6, 8, 12, and 24 hours after sample addition, and replenish with an equal amount of PBS in time; 9) After sampling, send the sample liquid to detect the PQQ-2Na content, and calculate the permeability of PQQ-2Na according to the following formula.

[0054] ;

[0055] Permeability % = Q n / C0*100%

[0056] Where C n represents the DPHP concentration in the permeate at the nth time point, C i represents the concentration of the analyte in the permeate at time point i, V s represents the volume of the receiving cell, V represents the sampled volume of the receiving solution, and S represents the effective permeation area of ​​the diffusion cell. i = 1 to n - 1 defines the complete range of historical sampling, ensuring that the cumulative permeation calculation includes both all previously removed drug and the current remaining drug, accurately reflecting the mass balance of the diffusion process.

[0057] Q n is the cumulative permeation amount, and C0 is the initial concentration of PQQ-2Na (100 mg / ml).

[0058] Comparing Examples 1-4 with Comparative Example 1, it can be seen that the penetration effect of Comparative Example 1 (adding only PQQ-2Na) is weak, and the addition of subtilisin sodium in Examples 1-4 can promote the efficient penetration and absorption of PQQ-2Na. The permeability of Example 4 (adding 0.5% subtilisin sodium) increased by 15 times, while the permeability of Comparative Example 3 (adding 1% bis-diethoxydiglycol cyclohexane 1,4-dicarboxylate) increased by only 7 times. Example 4 is significantly better than Comparative Example 3 in promoting penetration.

[0059] 3. Zebrafish embryo model test based on SDS stimulation

[0060] The compositions of Examples 5-7 and Comparative Examples 7-8 were used as test materials to conduct a zebrafish embryo model test:

[0061] SDS-stimulated zebrafish embryo experiment: The frequency of spin movements in zebrafish embryos is directly related to the external stimulus they experience. A zebrafish embryo stimulation model was established using sodium dodecyl sulfate (SDS) as a modeling agent. Normally developed 24 hpf embryos were treated with 200 μL of a sample-modeling agent mixture and incubated in a (28.5±0.5)°C incubator for 15 minutes. A blank control group, a negative control (model group), and a positive control (dipotassium glycyrrhizate) were also included. The soothing efficacy of the sample was assessed using the number of embryonic spin movements. Based on the experimental validity, the sample test group significantly reduced the stimulating effect of sodium dodecyl sulfate (SDS) on zebrafish embryos compared to the model group, indicating that the test compound exhibits an anti-irritant effect at this concentration, providing support for evaluating its soothing efficacy. The stimulation intensity was calculated using the formula = n / m × 100%, where n is the average number of spin movements of zebrafish embryos in the treated group and m is the average number of spin movements of zebrafish embryos in the blank control group. Specific results can be found in Figure 2 .

[0062] from Figure 2 The experimental results show that both Comparative Example 7 (adding 0.4% of sodium subtilisin) and Comparative Example 8 (adding only PQQ-2Na) have a certain effect of reducing the irritation of zebrafish embryos; comparing Example 7 with Comparative Examples 7-8, due to the high concentration of sodium subtilisin added, the combined use of sodium subtilisin and PQQ-2Na does not change significantly compared with the use of either alone; comparing Examples 5-6 with Comparative Example 8, when the content of sodium subtilisin is reduced, it is found that the combined use of sodium subtilisin and PQQ-2Na can still significantly reduce the irritation, indicating that the combined use of sodium subtilisin and PQQ-2Na has a certain soothing effect.

[0063] 4. Tyrosinase inhibition test and DPPH free radical scavenging test

[0064] (1) Tyrosinase inhibition rate experiment

[0065] Prepare L-tyrosine test solution (2.550mmol / L) for later use, and prepare sample solutions according to Examples 5-7 and Comparative Examples 7-8 for later use. In a 96-well plate, add samples according to the sample blank group, sample reaction blank group, solvent blank group, and solvent reaction group, respectively, with 3 replicate wells for each group. First, add L-tyrosine solution, sample solution / water, and PBS buffer to each well at once, mix thoroughly, and react at 37°C in the dark for 10 minutes. Then, add 20ul of tyrosinase solution to each well in turn, mix and react at 37°C for 5 minutes ± 5 seconds, and immediately use a microplate reader to measure the absorbance at 475nm. The amount added to each well is as shown in Table 4:

[0066] Table 4

[0067]

[0068] Tyrosinase inhibition rate was calculated according to the formula = (1 - (Td-Tc) / (Tb-Ta)) × 100%

[0069] (2) DPPH free radical scavenging experiment:

[0070] Prepare DPPH test solution and adjust its absorbance to about 0.7 at 517nm at room temperature. Prepare sample solutions of Examples 5-7, Comparative Example 7, and Comparative Example 8 for later use. Add samples to a 96-well plate according to the sample group, blank group, and control group, with 3 replicates per group. After 30 minutes of reaction in the dark, use a microplate reader to measure the absorbance at 517nm. The amount added to each well is as follows:

[0071] Sample (sample group): sample solution 100uL + DPPH alcohol solution 100uL

[0072] Blank group: 100uL sample solution + 100uL anhydrous ethanol

[0073] Control group: 100uL DPPH alcohol solution + 100uL water

[0074] Calculate the DPPH free radical scavenging rate according to the formula = (1-(A sample - A blank ) / A control ) × 100%

[0075] The Bliss independence model method was used to calculate the Combination Index (CI), and the calculation formula is as follows:

[0076] CI=E AB / (E A +E B -E A ×E B );

[0077] Among them, E AB Indicates the effect of the combination of two drugs, E A 、E B Indicates the effect of the drug when used alone, E A ×E B Indicates the expected effect of the combination of two drugs; when CI>1, it means that the two drugs have a synergistic effect, CI=1 means that the two drugs have an additive effect, and CI<1 means that the two drugs have an antagonistic effect. The test results of tyrosinase inhibition and DPPH free radical scavenging are calculated as shown in Table 5:

[0078] Table 5 Calculation results of synergy index of tyrosinase inhibition experiment and DPPD free radical scavenging experiment

[0079]

[0080] From the tyrosinase inhibition experiment and calculation results, it can be seen that the samples prepared in Examples 5-7 are compared with Comparative Examples 7-8 (adding subtilisin sodium and PQQ-2Na separately). The combined use of drugs, such as Examples 5-7, has a significant inhibitory effect on tyrosinase. Neither PQQ-2Na nor subtilisin sodium alone shows a significant inhibitory effect, and the synergistic index CI calculation result is >1, indicating that the combination of PQQ-2Na and subtilisin sodium has a good synergistic inhibitory effect on tyrosinase activity.

[0081] From the results of the DPPH radical scavenging experiment, it can be seen that the DPPH radical scavenging effects of Comparative Example 7 (only adding lipopeptide sodium) and Comparative Example 8 (only adding PQQ-2Na) are average and significantly lower than those of Examples 5-7; and the synergistic index CI>1, indicating that the combined use of PQQ-2Na and lipopeptide sodium produces a significant synergistic effect in scavenging free radicals.

[0082] In summary, after adding sodium subtilisin to Examples 5-7, the tyrosinase inhibition rate and DPPH free radical scavenging rate were significantly improved compared with Comparative Examples 7-8, indicating that the synergistic antioxidant effect of sodium subtilisin and PQQ-2Na was significantly improved, and had a whitening effect.

[0083] 5. Antibacterial effect

[0084] The antibacterial efficacy of the compositions of Examples 5 to 7 and Comparative Examples 7 to 11 was verified using them as test substances.

[0085] Test strains and numbers: Staphylococcus aureus ATCC 6538, Propionibacterium acnes BNCC336649

[0086] Bacterial concentration: Staphylococcus aureus ATCC 6538 3×10 6 CFU / mL, Pseudomonas acnes 9.5×10 6 CFU / mL

[0087] Test method: QB / T2738-2012 Evaluation method for the antibacterial and antimicrobial effects of daily chemical products 7.3 Antibacterial effect test method for antibacterial daily chemical products (suspension quantitative method). Pipette the test bacterial solution and mix it evenly. Let it sit for 24 hours. If the antibacterial rate is ≥50-90%, it indicates that the test sample has antibacterial effect. If the antibacterial rate is >90%, it indicates that the test sample has strong antibacterial effect.

[0088] Test steps:

[0089] a) Dilute the test bacterial suspension 0 appropriately with PBS solution to the following concentration: take 0.1 mL and drop it into 5.0 mL of control sample solution (PBS). The number of recovered bacteria is 1×10 4 ~9×10 4 cfu / mL.

[0090] b) Pipette 50 mL of the test sample into a sterile blue-capped bottle and incubate at 20°C for 5 minutes.

[0091] d) Pipette 1.0 mL of the test bacterial solution into the blue-capped bottle containing 50 mL of the test sample solution, mix quickly, and place on a horizontal shaker at 150 rpm, and start the timer immediately.

[0092] e) After the set time, take 0.5 mL of the test bacteria and sample mixture and add it to a test tube containing 4.5 mL of sterilized PBS and mix thoroughly.

[0093] f) After 10 minutes, pipette 1 mL of the sample solution (or, after appropriate dilution, two to three dilutions thereof) into a sterile plate. Inoculate two sterile plates for each sample solution or dilution. Pour 15 mL of nutrient agar (for bacteria) or Sabouraud agar (for Candida albicans) cooled to 40°C–45°C. Rotate the plate for thorough homogenization. After the agar solidifies, invert the plate. Incubate at 36°C±1°C for 48 hours±2 hours (for bacteria) or 72 hours±3 hours (for Candida albicans), and then count the viable colonies.

[0094] g) Substitute PBS for the test sample and follow the above steps to serve as the control sample.

[0095] h) Calculate the inhibition rate, the results are shown in Table 6.

[0096] Table 6 Antibacterial rates of the compositions of Examples 5 to 7 and Comparative Examples 7 to 11

[0097]

[0098] The Bliss independent model method (the same formula as above) was used to calculate the synergistic index of the composition in terms of antibacterial activity. The calculation results are shown in Table 7:

[0099] Table 7 Synergistic index (CI value) of the composition in terms of antibacterial activity

[0100]

[0101] The data show that Comparative Examples 7, 9, and 10 (adding only sodium subtilisin) had no inhibitory effect on Staphylococcus epidermidis. Adding 0.3% or more (Comparative Examples 10 and 7) showed some antibacterial effect against P. acnes. Comparative Examples 8 and 11 (adding only PQQ-2Na and 1,2-pentanediol) showed no antibacterial effect against either species. These results demonstrate that sodium subtilisin is a key component in the antibacterial composition of the present invention for inhibiting P. acnes. While PQQ-2Na alone did not exhibit significant inhibitory effect, its combination with sodium subtilisin exhibited a synergistic inhibitory effect against P. acnes. The synergistic antibacterial effect of PQQ-2Na increased with increasing sodium subtilisin addition. PQQ-2Na also had some inhibitory effect against Staphylococcus epidermidis.

[0102] The above are only preferred embodiments of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A composition containing PQQ, characterized in that including pyrroloquinoline quinone or its sodium salt and subtilisin sodium; The mass ratio of pyrroloquinoline quinone or its sodium salt to subtilisin sodium is (0.02-0.1): (0.05-0.5).

2. The composition according to claim 1, characterized in that The mass ratio of pyrroloquinoline quinone disodium salt to subtilisin sodium is 0.02: (0.2~0.4) or 0.1: (0.05~0.5).

3. The composition according to claim 1, characterized in that The mass ratio of pyrroloquinoline quinone disodium salt to subtilisin sodium is 0.02:0.2, or 0.02:0.3, or 0.02:0.4, or 0.1:0.05, or 0.1:0.1, or 0.1:0.3, or 0.1:0.

5.

4. Use of the composition according to any one of claims 1 to 3 in the preparation of skin care products.

5. The use according to claim 4, characterized in that The skin care products have the effects of soothing, anti-oxidation, whitening and / or antibacterial.

6. The use according to claim 5, characterized in that The antibacterial activity includes anti-Staphylococcus aureus and / or Propionibacterium acnes.

7. A skin care product, characterized in that The invention comprises the composition and auxiliary materials described in claims 1 to 3.

8. The skin care product according to claim 7, characterized in that The mass fraction of the composition is 0.15% to 0.6%.

9. The skin care product according to claim 8, characterized in that The auxiliary materials include pentanediol and water.

Images